Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia.
Leuk Res
; 15(5): 289-96, 1991.
Article
em En
| MEDLINE
| ID: mdl-2046382
ABSTRACT
Allogeneic bone marrow transplantation is the only way to cure patients with Ph1+ chronic myeloid leukemia. It is commonly assumed that, in order to obtain a cure for the patients, the leukemic clone must be completely destroyed by the conditioning treatment and the donor's bone marrow must repopulate the hemopoietic niches leading to a "complete chimera". However, cytogenetic analyses, supported by molecular ones, indicate that Ph1+ cells, far from being completely destroyed by chemo-radiotherapy may persist for a long time, probably in the majority of the patients. As demonstrated by the outcome of patients receiving T-cell depleted marrow, immune mechanisms must be involved in controlling and progressively reducing the size of the residual leukemic clone. Furthermore, immunodulating therapeutic strategies, represented by cyclosporin-A discontinuation or alpha interferon treatment, may successfully reduce the Ph1+ cell population even after a full relapse.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Transplante de Medula Óssea
Limite:
Humans
Idioma:
En
Revista:
Leuk Res
Ano de publicação:
1991
Tipo de documento:
Article
País de afiliação:
Itália